US Stock Insider Trading | SpyGlass Pharma disclosed 15 insider transactions on February 11

2026-02-24 09:07:48

Abstract generation in progress

On February 11, 2026, SpyGlass Pharma (SGP) disclosed 15 insider trades. Shareholder RA CAPITAL MANAGEMENT, L.P., holding over 10%, purchased 3.442 million shares on February 9, 2026.

[Recent Insider Trades]

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 11, 2026	Shareholder >10%	BASKETT FOREST, Chang Carmen, Florence Anthony A. Jr., Makhzoumi Mohamad, Mathers Edward T, New Enterprise Associates 17, L.P., SANDELL SCOTT D, Walker Paul Edward, Yang Rick	February 9, 2026	Buy	8.4375 million	16.00	$135 million
February 11, 2026	Director	Khan Bilal Arshad, Pardo Geoffrey B	February 9, 2026	Buy	447,500	16.00	$7.16 million
February 11, 2026	Shareholder >10%	Behbahani Ali, RA CAPITAL MANAGEMENT, L.P.	February 9, 2026	Buy	4.6275 million	16.00	$74.04 million
February 10, 2026	Shareholder >10%	Vensana Capital I GP, LLC	February 9, 2026	Buy	165,000	16.00	$2.64 million
February 10, 2026	Director	Nielsen Kirk G.	February 9, 2026	Buy	165,000	16.00	$2.64 million

[Company Profile]

SpyGlass Pharma, Inc. was incorporated under Delaware law on January 7, 2019. The company is a late-stage biopharmaceutical firm currently initiating Phase 3 clinical trials for its lead product, an IOL-mounted, controlled-release drug delivery system designed to treat glaucoma by delivering prostaglandin analogs. Its mission is to significantly improve the lives of patients with chronic eye diseases through the development of long-lasting drug delivery solutions, enabling patients and surgeons to have confidence in long-term disease management and vision preservation.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.